Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib Combined With APG-2575 in Children With R/R Ph+ ALL
NCT05495035Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olverembatinib and lisaftoclax in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-limiting toxicity at 42 days, Objective Response Rate at 132 days and 3 more. Started Sep 2022; status: recruiting.
02
Drugs
olverembatiniblisaftoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05495035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495035.